ZOPHREN 2 mg/ml, solution for injection in an ampoule (IV) 5 ampoules of 4 ml
Active ingredients: Ondansetron hydrochloride hydrate, Ondansetron
Commercialized according to BDPMANSM noticeDispensing in France: Prescription only
Solution for injection5 ampoules of 4 mlintraveineuse
Supply disruption
Package details
Original BDPM fields are shown in French.
- Official name
- ZOPHREN 2 mg/ml, solution injectable en ampoule (IV)
- Pharmaceutical form
- solution injectable
- Route of administration
- intraveineuse
- Presentation description
- 5 ampoule(s) en verre de 4 ml
- Marketing authorisation holder
- SANDOZ
- Reimbursement according to BDPM
- —
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 28 Nov 2023
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
65991171CIP75568320CIP133400955683209Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| CHLORHYDRATE D'ONDANSÉTRON DIHYDRATÉsolution | 2,50 mg · 1 ml | SA |
| ONDANSÉTRONsolution | 2 mg · 1 ml | FT |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Other packages of this medicine
The same medicine in another pack size, according to BDPM.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.